Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling

British Journal of Dermatology

Volumn 171, Issue 1, 2014, Pages 97-107

  Johnston, A ^a   Guzman, A M ^a   Swindell, W R ^a   Wang, F ^a   Kang, S ^b   Gudjonsson, J E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 22; MESSENGER RNA; PHOSPHOPROTEIN; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIMETABOLITE; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MRNA EXPRESSION ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; TISSUE REACTION; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; CHRONIC DISEASE; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; TISSUE MICROARRAY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMETABOLITES; BIOLOGICAL PRODUCTS; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, INTERLEUKIN-17; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84904872147     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12937     Document Type: Article

References (42)

1. Moreland LW, Schiff MH, Baumgartner SW, et al,. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
2. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
3. Mease PJ, Goffe BS, Metz J, et al,. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-90.
4. Fowler JF, Duh MS, Rovba L, et al,. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008; 59: 772-80.
5. Wilson NJ, Boniface K, Chan JR, et al,. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
6. Hijnen D, Knol EF, Gent YY, et al,. CD8+ T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol 2013; 133: 973-9.
7. Res PC, Piskin G, de Boer OJ, et al,. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010; 5: e14108.
8. Eyerich S, Eyerich K, Pennino D, et al,. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-85.
9. Johnston A, Fritz Y, Dawes SM, et al,. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol 2013; 190: 2252-62.
10. Ge D, You Z,. Expression of interleukin-17RC protein in normal human tissues. Int Arch Med 2008; 1: 19.
11. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, et al,. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677-87.
12. Kryczek I, Bruce AT, Gudjonsson JE, et al,. Induction of IL-17 + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733-41.
13. Johnston A, Gudjonsson JE, Aphale A, et al,. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol 2011; 131: 329-37.
14. Teunissen MB, Koomen CW, de Waal Malefyt R, et al,. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-9.
15. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H,. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
16. Nickoloff BJ, Xin H, Nestle FO, Qin JZ,. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25: 568-73.
17. Swindell WR, Xing X, Stuart PE, et al,. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One 2012; 7: e34594.
18. Bolstad BM, Collin F, Brettschneider J, et al,. Quality assessment of Affymetrix GeneChip Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. (, R Gentleman, V Carey, W Huber, RA Irizarry, S Dudoit, eds), New York, NY: Springer, 2005, 33-47.
19. Popova T, Mennerich D, Weith A, Quast K,. Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues. BMC Genomics 2008; 9: 91.
20. Irizarry RA, Bolstad BM, Collin F, et al,. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.
21. Liu WM, Mei R, Di X, et al,. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002; 18: 1593-9.
22. Smyth GK,. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:Article3.
23. Stalteri MA, Harrison AP,. Interpretation of multiple probe sets mapping to the same gene in Affymetrix GeneChips. BMC Bioinformatics 2007; 8: 13.
24. Lottaz C, Yang X, Scheid S, Spang R,. OrderedList-a bioconductor package for detecting similarity in ordered gene lists. Bioinformatics 2006; 22: 2315-16.
25. Johnston A, Xing X, Swindell WR, et al,. Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis. Hum Mol Genet 2013; 22: 1807-15.
26. Falcon S, Gentleman R,. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23: 257-8.
27. Elder JT, Fisher GJ, Zhang QY, et al,. Retinoic acid receptor gene expression in human skin. J Invest Dermatol 1991; 96: 425-33.
28. Wang F, Smith N, Maier L, et al,. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol 2012; 167: 92-102.
29. Leonardi CL, Powers JL, Matheson RT, et al,. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
30. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
31. Barker J, Hoffmann M, Wozel G, et al,. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109-17.
32. Mrowietz U, Kragballe K, Reich K, et al,. An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 2013; 168: 374-80.
33. Lizzul PF, Aphale A, Malaviya R, et al,. Differential expression of phosphorylated NF-κB/RelA in normal and psoriatic epidermis and downregulation of NF-κB in response to treatment with etanercept. J Invest Dermatol 2005; 124: 1275-83.
34. Gottlieb AB, Chamian F, Masud S, et al,. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-9.
35. Zaba LC, Cardinale I, Gilleaudeau P, et al,. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-94.
36. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al,. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124: 1022-30.e395.
37. Hartupee J, Liu C, Novotny M, et al,. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007; 179: 4135-41.
38. Leonardi C, Matheson R, Zachariae C, et al,. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
39. Papp KA, Langley RG, Sigurgeirsson B, et al,. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412-21.
40. Papp KA, Leonardi C, Menter A, et al,. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
41. Krueger JG, Fretzin S, Suárez-Fariñas M, et al,. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145-54.e9.
42. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al,. Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 2010; 125: 1261-8.e9.